应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
PCRX Pacira Pharmaceuticals
已收盘 07-17 16:00:00 EDT
20.99
-0.38
-1.78%
盘后
21.04
+0.05
+0.24%
18:56 EDT
最高
21.76
最低
20.66
成交量
110.11万
今开
21.20
昨收
21.37
日振幅
5.15%
总市值
9.77亿
流通市值
9.67亿
总股本
4,655万
成交额
2,312万
换手率
2.39%
流通股本
4,606万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
Pacira Biosciences, Inc.盘中异动 早盘大幅上涨5.14%报21.39美元
自选股智能写手 · 07-11
Pacira Biosciences, Inc.盘中异动 早盘大幅上涨5.14%报21.39美元
Pacira Biosciences, Inc.盘中异动 快速下跌5.28%报21.54美元
自选股智能写手 · 07-03
Pacira Biosciences, Inc.盘中异动 快速下跌5.28%报21.54美元
BUZZ-Pacira止痛药仿制药在美获批,业绩下滑
Reuters · 07-03
BUZZ-Pacira止痛药仿制药在美获批,业绩下滑
Needham:重申Pacira BioSciences(PCRX.US)评级
证券之星 · 07-03
Needham:重申Pacira BioSciences(PCRX.US)评级
Pacira Biosciences, Inc.盘中异动 早盘股价大跌6.25%
自选股智能写手 · 07-02
Pacira Biosciences, Inc.盘中异动 早盘股价大跌6.25%
Pacira Biosciences, Inc.盘中异动 股价大涨5.02%报30.73美元
自选股智能写手 · 05-30
Pacira Biosciences, Inc.盘中异动 股价大涨5.02%报30.73美元
HC Wainwright & Co.:重申Pacira BioSciences(PCRX.US)评级,由买入调整至买入评级, 目标价57.00美元。
智通财经 · 05-09
HC Wainwright & Co.:重申Pacira BioSciences(PCRX.US)评级,由买入调整至买入评级, 目标价57.00美元。
Needham:维持Pacira BioSciences(PCRX.US)评级,由买入调整至买入评级, 目标价由45.00美元调整至43.00美元。
智通财经 · 05-08
Needham:维持Pacira BioSciences(PCRX.US)评级,由买入调整至买入评级, 目标价由45.00美元调整至43.00美元。
Pacira Biosciences Inc 预计每股收益 63 美分 - 财报前瞻
Reuters · 04-29
Pacira Biosciences Inc 预计每股收益 63 美分 - 财报前瞻
Needham:重申Pacira BioSciences(PCRX.US)评级,由买入调整至买入评级, 目标价45.00美元。
智通财经 · 04-09
Needham:重申Pacira BioSciences(PCRX.US)评级,由买入调整至买入评级, 目标价45.00美元。
Pacira Biosciences, Inc.2023财年实现净利润41.96百万美元,同比增加163.73%
自选股智能写手 · 03-08
Pacira Biosciences, Inc.2023财年实现净利润41.96百万美元,同比增加163.73%
美国研究综述-Highpeak Energy、Nordstrom、Victoria'S Secret & Co
Reuters · 03-07
美国研究综述-Highpeak Energy、Nordstrom、Victoria'S Secret & Co
Pacira Biosciences Inc 报告截至 12 月的季度业绩 - 收益摘要
Reuters · 02-29
Pacira Biosciences Inc 报告截至 12 月的季度业绩 - 收益摘要
Pacira Biosciences Inc 预计每股收益 88 美分 - 财报前瞻
Reuters · 02-27
Pacira Biosciences Inc 预计每股收益 88 美分 - 财报前瞻
Pacira Biosciences Inc 预计每股收益 88 美分 - 财报前瞻
Reuters · 02-23
Pacira Biosciences Inc 预计每股收益 88 美分 - 财报前瞻
Pacira Biosciences Inc盘中异动 早盘股价大跌5.10%
自选股智能写手 · 02-07
Pacira Biosciences Inc盘中异动 早盘股价大跌5.10%
暂无数据
公司概况
公司名称:
Pacira Pharmaceuticals
所属市场:
NASDAQ
上市日期:
--
主营业务:
Pacira BioSciences, Inc.是一家专业制药公司,专注于医药产品的开发、商业化和制造,该公司专有的DepoFoam药物传递技术,主要用于医院和门诊手术中心。2011年10月28日,美国食品和药物管理局( FDA)批准该公司的新药申请,即公司的主导产品EXPAREL,这是一种脂质体注射布比卡因,酰胺类局麻药表示为渗透进入手术部位,术后镇痛长达72小时。该公司认为EXPAREL解决了长效非阿片类镇痛手术后,一个显著的医疗需要,从而简化手术后疼痛控制和减少阿片类药物用量,从而提高患者的治疗效果,提高医院经济效益。该公司开发的内部销售团队完全致力于EXPAREL商业化,该公司已于2012年4月把产品推出市场。此外,继2013年10月1日生效的一个实验方案,该公司任命CrossLink BioScience, LLC(CrossLink),为一个为期五年的独家第三方分销商推广和销售EXPAREL在美国骨科和脊柱外科手术成立一个团队,如果某些地区和账户如有变更,需要经过双方同意才能调整。 该公司成立于2006年12月,并自2007年3月已开展关于EXPAREL业务。
发行价格:
--
{"stockData":{"symbol":"PCRX","market":"US","secType":"STK","nameCN":"Pacira Pharmaceuticals","latestPrice":20.99,"timestamp":1721246400000,"preClose":21.37,"halted":0,"volume":1101070,"hourTrading":{"tag":"盘后","latestPrice":21.04,"preClose":20.99,"latestTime":"18:56 EDT","volume":98912,"amount":2077311.03,"timestamp":1721256960159},"delay":0,"floatShares":46057338,"shares":46546148,"eps":1.416418,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.38,"latestTime":"07-17 16:00:00 EDT","open":21.2,"high":21.76,"low":20.66,"amount":23121377.73856,"amplitude":0.051474,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.416418,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1721289600000},"adr":0,"listingDate":1296709200000,"adjPreClose":21.37,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":21.3,"preClose":21.37,"latestTime":"09:28 EDT","volume":355,"amount":7510.4701700000005,"timestamp":1721222910528},"postHourTrading":{"tag":"盘后","latestPrice":21.04,"preClose":20.99,"latestTime":"18:56 EDT","volume":98912,"amount":2077311.03,"timestamp":1721256960159},"volumeRatio":0.914741,"optionData":{"bulkOrders":[{"symbol":"PCRX","call":true,"expireDate":1723780800000,"strike":"20.0","timestamp":1721243343641,"price":4.579999923706055,"volume":1516,"amount":694328,"type":"*"},{"symbol":"PCRX","call":false,"expireDate":1723780800000,"strike":"20.0","timestamp":1721243343641,"price":3.950000047683716,"volume":1516,"amount":598820,"type":"*"}]},"impliedVol":1.8332,"impliedVolPercentile":0.9881},"requestUrl":"/m/hq/s/PCRX/tweets","defaultTab":"tweets","newsList":[{"id":"2450363481","title":"Pacira Biosciences, Inc.盘中异动 早盘大幅上涨5.14%报21.39美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2450363481","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450363481?lang=zh_cn&edition=full","pubTime":"2024-07-11 21:42","pubTimestamp":1720705345,"startTime":"0","endTime":"0","summary":"北京时间2024年07月11日21时42分,Pacira Biosciences, Inc.股票出现波动,股价急速拉升5.14%。Pacira Biosciences, Inc.股票所在的制药行业中,整体跌幅为0.03%。Pacira Biosciences, Inc.公司简介:Pacira BioSciences Inc 是一家非阿片类疼痛管理和再生健康解决方案的提供商,致力于推进和改善医疗从业者及其患者的效果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240711214225aef93d6e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240711214225aef93d6e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"2448488988","title":"Pacira Biosciences, Inc.盘中异动 快速下跌5.28%报21.54美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2448488988","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448488988?lang=zh_cn&edition=full","pubTime":"2024-07-03 21:30","pubTimestamp":1720013436,"startTime":"0","endTime":"0","summary":"北京时间2024年07月03日21时30分,Pacira Biosciences, Inc.股票出现波动,股价大幅下挫5.28%。Pacira Biosciences, Inc.股票所在的制药行业中,整体跌幅为0.79%。Pacira Biosciences, Inc.公司简介:Pacira BioSciences Inc 是一家非阿片类疼痛管理和再生健康解决方案的提供商,致力于推进和改善医疗从业者及其患者的效果。消息层面,截至21时30分,《加皇资本市场维持Pacira BioSciences买入评级,下调目标价至45美元》资讯为影响Pacira Biosciences, Inc.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240703213036aef7c9a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240703213036aef7c9a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","PCRX"],"gpt_icon":0},{"id":"2448881104","title":"BUZZ-Pacira止痛药仿制药在美获批,业绩下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2448881104","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448881104?lang=zh_cn&edition=full","pubTime":"2024-07-03 20:16","pubTimestamp":1720008983,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 7月3日 - ** Pacira BioSciences 股价盘前下跌 ~1% 至 22.50 美元** 美国 FDA 周二批准了 PCRX 非阿片类止痛药 Exparel 的仿制药,导致该公司股价在收盘时下跌 20** FDA 网站显示江苏恒瑞医药的布比卡因脂质体申请获得批准** 券商 Truist Securities 称批准结果符合其预期,并称市场反应过激,因为尽管获得批准,但仿制药的上市途径有限** 截至上次收盘,股价累计下跌 32.6","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX","BK4007","BUZZ"],"gpt_icon":0},{"id":"2448167293","title":"Needham:重申Pacira BioSciences(PCRX.US)评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2448167293","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448167293?lang=zh_cn&edition=full","pubTime":"2024-07-03 01:43","pubTimestamp":1719942204,"startTime":"0","endTime":"0","summary":"Needham:重申Pacira BioSciences(PCRX.US)评级,由买入调整至买入评级,目标价由43.00美元调整至43.00美元。Pacira BioSciences(PCRX.US)公司简介:Pacira BioSciences Inc是一家提供非阿片类药物疼痛管理和再生健康解决方案的供应商,致力于为医疗保健从业者及其患者推进和改善结果。该公司推出了EXPAREL,它利用DepoFoam,这是一种产品输送技术,可以在不改变分子结构的情况下封装药物,并在所需的时间内释放药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024070301453395681f6e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024070301453395681f6e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PCRX"],"gpt_icon":0},{"id":"2448503154","title":"Pacira Biosciences, Inc.盘中异动 早盘股价大跌6.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2448503154","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448503154?lang=zh_cn&edition=full","pubTime":"2024-07-02 21:31","pubTimestamp":1719927062,"startTime":"0","endTime":"0","summary":"北京时间2024年07月02日21时31分,Pacira Biosciences, Inc.股票出现异动,股价大幅跳水6.25%。Pacira Biosciences, Inc.股票所在的制药行业中,整体跌幅为0.90%。其相关个股中,Sunshine Biopharma Inc C/Wts 、Evoke Pharma, Inc.、大自然药业涨幅较大,苏轩堂、Sunshine Biopharma Inc.、Fsd Pharma Inc.较为活跃,换手率分别为1.49%、0.76%、0.67%,振幅较大的相关个股有Sunshine Biopharma Inc C/Wts 、Evoke Pharma, Inc.、Pacira Biosciences, Inc.,振幅分别为56.34%、13.29%、5.52%。Pacira Biosciences, Inc.公司简介:Pacira BioSciences Inc 是一家非阿片类疼痛管理和再生健康解决方案的提供商,致力于推进和改善医疗从业者及其患者的效果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240702213102941f31f7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240702213102941f31f7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","PCRX"],"gpt_icon":0},{"id":"2439624022","title":"Pacira Biosciences, Inc.盘中异动 股价大涨5.02%报30.73美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2439624022","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439624022?lang=zh_cn&edition=full","pubTime":"2024-05-30 23:51","pubTimestamp":1717084266,"startTime":"0","endTime":"0","summary":"北京时间2024年05月30日23时51分,Pacira Biosciences, Inc.股票出现异动,股价大幅拉升5.02%。截至发稿,该股报30.73美元/股,成交量18.5556万股,换手率0.40%,振幅4.36%。Pacira Biosciences, Inc.股票所在的制药行业中,整体涨幅为0.56%。Pacira Biosciences, Inc.公司简介:Pacira BioSciences Inc 是一家非阿片类疼痛管理和再生健康解决方案的提供商,致力于推进和改善医疗从业者及其患者的效果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240530235107941eb3bd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240530235107941eb3bd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","PCRX"],"gpt_icon":0},{"id":"2434670897","title":"HC Wainwright & Co.:重申Pacira BioSciences(PCRX.US)评级,由买入调整至买入评级, 目标价57.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2434670897","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434670897?lang=zh_cn&edition=full","pubTime":"2024-05-09 03:34","pubTimestamp":1715196897,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.:重申Pacira BioSciences(PCRX.US)评级,由买入调整至买入评级, 目标价57.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050903345987e173e8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050903345987e173e8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PCRX"],"gpt_icon":0},{"id":"2433742702","title":"Needham:维持Pacira BioSciences(PCRX.US)评级,由买入调整至买入评级, 目标价由45.00美元调整至43.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2433742702","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433742702?lang=zh_cn&edition=full","pubTime":"2024-05-08 18:47","pubTimestamp":1715165273,"startTime":"0","endTime":"0","summary":"Needham:维持Pacira BioSciences(PCRX.US)评级,由买入调整至买入评级, 目标价由45.00美元调整至43.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050818480287e028e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050818480287e028e0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PCRX"],"gpt_icon":0},{"id":"2431786247","title":"Pacira Biosciences Inc 预计每股收益 63 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2431786247","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431786247?lang=zh_cn&edition=full","pubTime":"2024-04-29 22:30","pubTimestamp":1714401039,"startTime":"0","endTime":"0","summary":" * Pacira Biosciences Inc 预计在5月1日公布截至2024年3月31日的业绩时,季度收入将有所增长() * 根据LSEG的数据,9位分析师的平均预期显示,这家总部位于佛罗里达州坦帕市的公司的营收有望从去年同期的1.6034亿美元增至1.6588亿美元,增幅为3.5%。* LSEG 分析师对 Pacira Biosciences Inc 的平均预期为每股收益 63 美分。* 华尔街对 Pacira Biosciences Inc 的 12 个月目标价中值为 45.00 美元,高于其上次收盘价 26.33 美元。4月29日 - 上一季度业绩。除非另有说明,否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX"],"gpt_icon":0},{"id":"2426169589","title":"Needham:重申Pacira BioSciences(PCRX.US)评级,由买入调整至买入评级, 目标价45.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2426169589","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2426169589?lang=zh_cn&edition=full","pubTime":"2024-04-09 18:35","pubTimestamp":1712658903,"startTime":"0","endTime":"0","summary":"Needham:重申Pacira BioSciences(PCRX.US)评级,由买入调整至买入评级, 目标价45.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404091835058b030e10&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404091835058b030e10&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PCRX"],"gpt_icon":0},{"id":"2417794322","title":"Pacira Biosciences, Inc.2023财年实现净利润41.96百万美元,同比增加163.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2417794322","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2417794322?lang=zh_cn&edition=full","pubTime":"2024-03-08 00:24","pubTimestamp":1709828695,"startTime":"0","endTime":"0","summary":"12月31日,Pacira Biosciences, Inc.公布财报,公告显示公司2023财年净利润为41.96百万美元,同比增加163.73%;其中营业收入为6.75亿美元,同比增加1.20%,每股基本收益为0.91美元。从资产负债表来看,Pacira Biosciences, Inc.总负债7.04亿美元,其中短期债务17.44百万美元,资产负债比为2.24,流动比率为0.06。机构评级:截至2023年12月31日,当前有10家机构对Pacira Biosciences, Inc.目标价做出预测,其中目标均价为45.30美元,其中最低目标价为36.00美元,最高目标价为57.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403080025018760fe42&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403080025018760fe42&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PCRX"],"gpt_icon":0},{"id":"2417781874","title":"美国研究综述-Highpeak Energy、Nordstrom、Victoria'S Secret & Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2417781874","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2417781874?lang=zh_cn&edition=full","pubTime":"2024-03-07 14:49","pubTimestamp":1709794169,"startTime":"0","endTime":"0","summary":" 路透社3月7日 - 华尔街证券分析师周四修改了对几家美国上市公司的评级和目标价,其中包括 Highpeak Energy、Nordstrom 和 Victoria'S Secret & Co。公司要闻 * Highpeak Energy Inc :Gerdes Energy Research将其评级从买入下调至卖出 * Nordstrom Inc :杰富瑞将其评级从买入下调至持有 * 维多利亚的秘密 :摩根大通将其股票评级从 \"中性 \"下调至 \"减持\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","UNFI","BK4588","IE00B19Z4B17.USD","BK4213","BK4095","CPB","LU1093756325.SGD","PCRX","TPVG","BK4196","ANF","NEWT","BK4139","VCCTF","JWN","VIAV","BHVN","HPKEW","BK4539","IE00B7SZL793.SGD","WCC","BK4020","BK4505","BK4212","BK4184","FL","BBIO","CYTK","ASTH","BK4102","HPK","TARS","IE0031619046.USD","IE00B66KJ199.SGD","ELEV","LU1093756168.USD","EWCZ","OSPN","ZYME","BK4094","BK4135","VSCO","BK4192","BK4220","BK4007","DMTK","AQST","BK4103","BK4104"],"gpt_icon":0},{"id":"2416752440","title":"Pacira Biosciences Inc 报告截至 12 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2416752440","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2416752440?lang=zh_cn&edition=full","pubTime":"2024-02-29 23:27","pubTimestamp":1709220455,"startTime":"0","endTime":"0","summary":" * Pacira Biosciences Inc 公布的截至12月底的季度调整后每股收益为89美分,高于去年同期的每股收益80美分。九位分析师对该季度的平均预期是每股收益 88 美分。华尔街预期为每股收益 75 美分至 98 美分。* 营收同比增长 5.4%,达到 1.8124 亿美元;分析师预期为 1.8166 亿美元。* Pacira Biosciences 公司公布的本季度每股收益为 50 美分。* 公司报告的季度净收入为 2487 万美元。* 本季度,Pacira Biosciences Inc 的股价下跌了 11.4%。华尔街对 Pacira Biosciences Inc 的 12 个月目标价中位数为 45.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PCRX"],"gpt_icon":0},{"id":"2414877032","title":"Pacira Biosciences Inc 预计每股收益 88 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2414877032","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2414877032?lang=zh_cn&edition=full","pubTime":"2024-02-27 21:59","pubTimestamp":1709042360,"startTime":"0","endTime":"0","summary":" * 帕西拉生物科学公司 将于2月29日公布截至2023年12月31日的财报,预计该公司的季度收入将有所增长。* LSEG 分析师对 Pacira Biosciences Inc 的平均预期为每股收益 88 美分。* 华尔街对 Pacira Biosciences Inc 的 12 个月目标价中位数为 45.00 美元,高于其最新收盘价 29.74 美元。2月27日 - 上一季度业绩。除非另有说明,所有数字均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX"],"gpt_icon":0},{"id":"2413179766","title":"Pacira Biosciences Inc 预计每股收益 88 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2413179766","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2413179766?lang=zh_cn&edition=full","pubTime":"2024-02-23 21:47","pubTimestamp":1708696068,"startTime":"0","endTime":"0","summary":" * 帕西拉生物科学公司 将于2月29日公布截至2023年12月31日的财报,预计该公司的季度收入将有所增长。* LSEG 分析师对 Pacira Biosciences Inc 的平均预期为每股收益 88 美分。* 华尔街对 Pacira Biosciences Inc 的 12 个月目标价中位数为 45.00 美元,高于其最新收盘价 29.97 美元。2月23日 - 上一季度业绩。除非另有说明,所有数字均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX"],"gpt_icon":0},{"id":"2409758592","title":"Pacira Biosciences Inc盘中异动 早盘股价大跌5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2409758592","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2409758592?lang=zh_cn&edition=full","pubTime":"2024-02-07 23:31","pubTimestamp":1707319898,"startTime":"0","endTime":"0","summary":"北京时间2024年02月07日23时31分,Pacira Biosciences Inc股票出现异动,股价大幅跳水5.10%。Pacira Biosciences Inc股票所在的制药行业中,整体涨幅为1.62%。Pacira Biosciences Inc公司简介:Pacira BioSciences Inc 是一家提供非阿片类药物疼痛管理和再生健康解决方案的供应商,致力于为医疗保健从业者及其患者推进和改善结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024020723313887e6edfa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024020723313887e6edfa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PCRX","BK4007","BFRI"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pacira.com","stockEarnings":[{"period":"1week","weight":0.0196},{"period":"1month","weight":-0.2403},{"period":"3month","weight":-0.2017},{"period":"6month","weight":-0.3265},{"period":"1year","weight":-0.4341},{"period":"ytd","weight":-0.3666}],"compareEarnings":[{"period":"1week","weight":0.0163},{"period":"1month","weight":0.0407},{"period":"3month","weight":0.1285},{"period":"6month","weight":0.1855},{"period":"1year","weight":0.2529},{"period":"ytd","weight":0.1884}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Pacira BioSciences, Inc.是一家专业制药公司,专注于医药产品的开发、商业化和制造,该公司专有的DepoFoam药物传递技术,主要用于医院和门诊手术中心。2011年10月28日,美国食品和药物管理局( FDA)批准该公司的新药申请,即公司的主导产品EXPAREL,这是一种脂质体注射布比卡因,酰胺类局麻药表示为渗透进入手术部位,术后镇痛长达72小时。该公司认为EXPAREL解决了长效非阿片类镇痛手术后,一个显著的医疗需要,从而简化手术后疼痛控制和减少阿片类药物用量,从而提高患者的治疗效果,提高医院经济效益。该公司开发的内部销售团队完全致力于EXPAREL商业化,该公司已于2012年4月把产品推出市场。此外,继2013年10月1日生效的一个实验方案,该公司任命CrossLink BioScience, LLC(CrossLink),为一个为期五年的独家第三方分销商推广和销售EXPAREL在美国骨科和脊柱外科手术成立一个团队,如果某些地区和账户如有变更,需要经过双方同意才能调整。 该公司成立于2006年12月,并自2007年3月已开展关于EXPAREL业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.615385,"avgChangeRate":0.042499},{"month":2,"riseRate":0.692308,"avgChangeRate":0.029842},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.007802},{"month":4,"riseRate":0.571429,"avgChangeRate":0.037069},{"month":5,"riseRate":0.571429,"avgChangeRate":0.025955},{"month":6,"riseRate":0.428571,"avgChangeRate":0.019619},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.023935},{"month":8,"riseRate":0.538462,"avgChangeRate":0.017969},{"month":9,"riseRate":0.384615,"avgChangeRate":-0.008174},{"month":10,"riseRate":0.230769,"avgChangeRate":-0.026814},{"month":11,"riseRate":0.692308,"avgChangeRate":0.066842},{"month":12,"riseRate":0.538462,"avgChangeRate":0.032185}],"exchange":"NASDAQ","name":"Pacira Pharmaceuticals","nameEN":"Pacira Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pacira Pharmaceuticals(PCRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Pacira Pharmaceuticals(PCRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Pacira Pharmaceuticals,PCRX,Pacira Pharmaceuticals股票,Pacira Pharmaceuticals股票老虎,Pacira Pharmaceuticals股票老虎国际,Pacira Pharmaceuticals行情,Pacira Pharmaceuticals股票行情,Pacira Pharmaceuticals股价,Pacira Pharmaceuticals股市,Pacira Pharmaceuticals股票价格,Pacira Pharmaceuticals股票交易,Pacira Pharmaceuticals股票购买,Pacira Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pacira Pharmaceuticals(PCRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Pacira Pharmaceuticals(PCRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}